Vizgen launches integrated Merscope in situ imaging platform

By The Science Advisory Board staff writers

March 1, 2021 -- Vizgen has launched its Merscope platform, a multiplexed, error-robust, single-cell in situ transcriptomic imaging technology.

Merscope is an integrated solution that combines single-cell and spatial genomics analysis. The system provides a streamlined workflow from sample preparation through data visualization for in situ analysis in fundamental biology and medicine applications.

Vizgen's Merscope is the first commercial solution to combine single-cell and spatial genomics analysis for advancing cellular and molecular biology research. Image courtesy of Vizgen.

Merscope is based on multiplexed error-robust fluorescence in situ hybridization (MERFISH) technology developed by Xiaowei Zhuang, PhD, a Howard Hughes Medical Institute investigator. Merscope provides combinatorial labeling, sequential imaging, and error-robust barcoding to provide nanometer-scale resolution across whole tissues, according to the company. The imaging-based approach enables hundreds of genes to be profiled within hundreds of thousands of cells in a single instrument run without the need for expensive sequencing.

Vizgen's commercially available equipment is designed for flexibility on any sample or tissue type and includes validated or custom gene panels, reagents, and consumables; fully automated instrumentation; and data visualization software.

The company will present the technology on March 2 at the Advances in Genome Biology and Technology (AGBT) 2021 General Meeting.

Vizgen debuts accelerator lab in the U.S.
Life sciences company Vizgen has established an accelerator lab in the U.S. to advance pharmaceutical research and development.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter